Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

New hope for psoriatic arthritis sufferers: experimental drug D-2570 enters phase 2 trial

NCT ID NCT07315061

First seen Jan 11, 2026 · Last updated May 21, 2026 · Updated 20 times

Summary

This study tests an experimental drug called D-2570 in people with active psoriatic arthritis, a condition causing joint pain and swelling. About 222 adults aged 18 to 70 will receive either D-2570 or a placebo to see if the drug reduces joint tenderness and swelling. The main goal is to check if more people on D-2570 achieve at least a 20% improvement in symptoms after 12 weeks.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for PSA (PSORIATIC ARTHRITIS) are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • West China School of Medicine

    RECRUITING

    Chengdu, Sichuan, 610041, China

Conditions

Explore the condition pages connected to this study.